Financial Personal
Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring
Ferring reported annual revenues of €2.2 billion, an increase of +1% at constant exchange rates, supported by robust sales performance in core franchise and legacy products Launches of Rebyota® and Adstiladrin® in United States provide major mid- to
SAINT-PREX, Switzerland -- Ferring today published its 2023 Annual Report showing the company’s annual revenues were €2.2 billion, a decrease of -4% on the previous year at actual exchange rates (AER), but an increase of +1% at constant exchange rates (CER). EBITDA increased by +€43 million (+12% at AER) to reach €406 million and operating profit for the year reached €139 million. Read More
Related
Share this page
Guest Posts by Easy Branches